The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...
An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...
Preparing to Initiate Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025Series B Financing Funds ...
Our fundamental challenge is not simply to create the data. Rather, it is to collect and analyze it systematically. Doing so ...
Increased menstrual blood loss can be hard to measure and may detract from a woman’s quality of life, but a range of ...
A systematic literature review found no evidence to support that physical exertion without rhabdomyolysis (muscle breakdown) or heat injury can cause sudden death for individuals with sickle cell ...
The society also recognized Tampa General and its academic partnership with the USF Health Morsani College of Medicine, which forms a multidisciplinary facility with all-encompassing cancer care that ...
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been ...
A systematic literature review found no evidence to support that physical exertion without rhabdomyolysis (muscle breakdown) or heat injury can cause sudden death for individuals with sickle cell ...
Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...
We can do better. We can build a system that provides coordinated high-quality care to every patient who needs it.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback